Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement. The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.
Our solution to endosomal entrapment has the potential to re-open myriad drug development pathways for macromolecule therapeutics lacking efficacy and to explore new targets considered “undruggable” by permeabilizing endo-lysosomal membranes, allowing trapped macromolecules to be released, increasing target engagement without negatively impacting the plasma membrane integrity.
Our solution to endosomal entrapment has the potential to re-open myriad drug development pathways for macromolecule therapeutics lacking efficacy and to explore new targets considered “undruggable” by permeabilizing endo-lysosomal membranes, allowing trapped macromolecules to be released, increasing target engagement without negatively impacting the plasma membrane integrity.
Location: Netherlands, Utrecht
Employees: 11-50
Total raised: $17.35M
Founded date: 2016
Investors 1
| Date | Name | Website |
| - | Aglaia Onc... | aglaia-onc... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.10.2021 | - | $17.35M | - |
Mentions in press and media 2
| Date | Title | Description |
| 11.10.2021 | Dutch biotech company Sapreme raises €15M to develop therapies to treat cancer; know more here | Utrecht, Netherlands-based Sapreme Technologies, a biotechnology company that works to improve the delivery and efficacy of macromolecule therapeutics to treat cancer, announced that it has secured €15M in its Series A round of funding. The... |
| 20.02.2019 | Sapreme Technologies in €6.8M EU Alliance | Sapreme Technologies, an Utrecht, the Netherlands-based biotech company developing a technology platform to enable the cytosolic delivery of macromolecule therapeutics, has been awarded a 6.8 M€ grant together with a multidisciplinary conso... |